Adverum Biotechnologies Inc (ADVM)
6.05
+0.30
(+5.22%)
USD |
NASDAQ |
Nov 22, 15:41
Adverum Biotechnologies Total Liabilities (Quarterly): 90.26M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 90.26M |
June 30, 2024 | 85.77M |
March 31, 2024 | 85.54M |
December 31, 2023 | 89.54M |
September 30, 2023 | 94.06M |
June 30, 2023 | 110.27M |
March 31, 2023 | 117.82M |
December 31, 2022 | 126.85M |
September 30, 2022 | 124.02M |
June 30, 2022 | 130.83M |
March 31, 2022 | 124.44M |
December 31, 2021 | 123.54M |
September 30, 2021 | 144.58M |
June 30, 2021 | 147.00M |
March 31, 2021 | 46.73M |
December 31, 2020 | 48.22M |
September 30, 2020 | 43.00M |
June 30, 2020 | 48.61M |
March 31, 2020 | 44.65M |
December 31, 2019 | 47.77M |
September 30, 2019 | 41.31M |
June 30, 2019 | 32.14M |
Date | Value |
---|---|
March 31, 2019 | 32.90M |
December 31, 2018 | 12.33M |
September 30, 2018 | 10.35M |
June 30, 2018 | 13.14M |
March 31, 2018 | 11.12M |
December 31, 2017 | 17.88M |
September 30, 2017 | 17.22M |
June 30, 2017 | 16.40M |
March 31, 2017 | 20.55M |
December 31, 2016 | 18.98M |
September 30, 2016 | 20.34M |
June 30, 2016 | 16.69M |
March 31, 2016 | 11.37M |
December 31, 2015 | 11.73M |
September 30, 2015 | 11.50M |
June 30, 2015 | 13.09M |
March 31, 2015 | 13.01M |
December 31, 2014 | 12.42M |
September 30, 2014 | 11.50M |
June 30, 2014 | 11.75M |
March 31, 2014 | 1.699M |
December 31, 2013 | 1.303M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
43.00M
Minimum
Sep 2020
147.00M
Maximum
Jun 2021
93.68M
Average
92.16M
Median
Total Liabilities (Quarterly) Benchmarks
EyePoint Pharmaceuticals Inc | 82.18M |
Cassava Sciences Inc | 57.11M |
Regenxbio Inc | 217.70M |
Editas Medicine Inc | 151.93M |
Apellis Pharmaceuticals Inc | 664.74M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 234.38M |
Shareholders Equity (Quarterly) | 144.12M |
Current Ratio | 5.824 |